Malcolm C Pike

List of Publications by Year
in descending order

118	9,062	66234	42291
papers	citations	42	92
		h-index	g-index

118	118	118	12075
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	1.4	8
2	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
3	Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1091.2021.	1.1	1
4	The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation. Breast Cancer Research and Treatment, 2022, 192, 321-329.	1.1	4
5	Association of contralateral breast cancer risk with mammographic density defined at higherâ€than â€conventional intensity thresholds. International Journal of Cancer, 2022, 151, 1304-1309.	2.3	3
6	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	3.0	8
7	Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer, 2021, 148, 2068-2078.	2.3	14
8	Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 927-935.	1.1	10
9	Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. Gynecologic Oncology, 2021, 162, 461-468.	0.6	8
10	Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology, 2021, , .	0.6	5
11	Interval breast cancer risk associations with breast density, family history and breast tissue aging. International Journal of Cancer, 2020, 147, 375-382.	2.3	22
12	Identification of novel epithelial ovarian cancer loci in women of African ancestry. International Journal of Cancer, 2020, 146, 2987-2998.	2.3	18
13	Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Research, 2020, 22, 138.	2.2	10
14	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. Epidemiology, 2020, 31, 402-408.	1.2	12
15	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
16	Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology, 2020, 6, e200421.	3.4	78
17	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
18	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49

#	Article	IF	Citations
19	Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women. Cancer Causes and Control, 2019, 30, 967-978.	0.8	14
20	â€œI am not a statisticâ€•ovarian cancer survivorsâ€™ views of factors that influenced their long-term survival. Gynecologic Oncology, 2019, 155, 461-467.	0.6	19
21	Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer. Radiology, 2019, 293, 81-88.	3.6	118
22	Automated Breast Density Measurements From Chest Computed Tomography Scans. Journal of Medical Systems, 2019, 43, 242.	2.2	1
23	Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews Cancer, 2019, 19, 339-348.	12.8	35
24	A comprehensive geneâ€"environment interaction analysis in Ovarian Cancer using genomeâ€•wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	2.3	12
25	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
26	Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. International Journal of Epidemiology, 2018, 47, 460-472.	0.9	33
27	MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women. International Journal of Cancer, 2018, 143, 823-830.	2.3	23
28	Observations on the origin of ovarian cortical inclusion cysts in women undergoing riskâ€•reducing salpingoâ€•oophorectomy. Histopathology, 2018, 72, 766-776.	1.6	13
29	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
30	Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. Breast Cancer Research and Treatment, 2018, 172, 487-496.	1.1	29
31	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
32	Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception, 2017, 95, 398-404.	0.8	14
33	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	2.3	25
34	Endogenous thrombin potential changes during the first cycle of oral contraceptive use. Contraception, 2017, 95, 456-463.	0.8	16
35	Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study. British Journal of Cancer, 2017, 117, 290-299.	2.9	30
36	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356

#	ARTICLE	IF	CITATIONS
37	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	2.9	13
38	Timing of births and oral contraceptive use influences ovarian cancer risk. International Journal of Cancer, 2017, 141, 2392-2399.	2.3	22
39	Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations—Reply. JAMA Oncology, 2017, 3, 417.	3.4	1
40	Dietary Factors Reduce Risk of Acute Pancreatitis in a Large Multiethnic Cohort. Clinical Gastroenterology and Hepatology, 2017, 15, 257-265.e3.	2.4	36
41	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
42	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. JAMA Oncology, 2016, 2, 1434.	3.4	189
43	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics and Gynecology, 2016, 127, 828-836.	1.2	39
44	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1114-1124.	1.1	32
45	A splicing variant of <i>TERT</i> identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal of Cancer, 2016, 139, 2646-2654.	2.3	7
46	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
47	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	2.9	39
48	Assessment of Multifactor Gene–Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	1.1	10
49	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	0.8	20
50	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	1.1	9
51	Clotting factor changes during the first cycle of oral contraceptive use. Contraception, 2016, 93, 70-76.	0.8	15
52	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
53	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	0.8	7
54	African Americans and Hispanics Remain at Lower Risk of Ovarian Cancer Than Non-Hispanic Whites after Considering Nongenetic Risk Factors and Oophorectomy Rates. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1094-1100.	1.1	33

#	Article	IF	Citations
55	Epithelial–Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
56	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
57	Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone. BioMed Research International, 2015, 2015, 1-9.	0.9	20
58	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
59	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i>-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
60	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
61	Estimating systemic exposure to ethinyl estradiol from an oral contraceptive. American Journal of Obstetrics and Gynecology, 2015, 212, 614.e1-614.e7.	0.7	8
62	The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic Oncology, 2015, 136, 505-511.	0.6	45
63	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
64	Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	1.9	26
65	Brian E. Henderson: In Memoriam (1937–2015). Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1437-1438.	1.1	0
66	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
67	Common variants at the<i>CHEK2</i>gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
68	Double-Blind Randomized 12-Month Soy Intervention Had No Effects on Breast MRI Fibroglandular Tissue Density or Mammographic Density. Cancer Prevention Research, 2015, 8, 942-951.	0.7	32
69	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676.	1.1	82
70	Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLoS ONE, 2015, 10, e0139013.	1.1	3
71	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
72	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13

#	Article	IF	Citations
73	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
74	Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis, 2014, 35, 1737-1744.	1.3	50
75	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. Cancer Research, 2014, 74, 5808-5818.	0.4	24
76	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	3.0	186
77	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
78	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	0.8	613
79	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
80	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes and Control, 2013, 24, 989-1004.	0.8	84
81	Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls. Cancer Prevention Research, 2013, 6, 811-821.	0.7	77
82	Biological Effects of Green Tea Capsule Supplementation in Pre-Surgery Postmenopausal Breast Cancer Patients. Frontiers in Oncology, 2013, 3, 298.	1.3	14
83	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	1.1	54
84	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	1.6	169
85	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
86	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal of Epidemiology, 2013, 42, 579-589.	0.9	146
87	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
88	Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal of Epidemiology, 2012, 176, 269-278.	1.6	76
89	Impact of Tamoxifen on Amount of Fibroglandular Tissue, Background Parenchymal Enhancement, and Cysts on Breast Magnetic Resonance Imaging. Breast Journal, 2012, 18, 527-534.	0.4	80
90	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncology, The, 2012, 13, 385-394.	5.1	753

#	ARTICLE	IF	CITATIONS
91	Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. European Radiology, 2012, 22, 2641-2647.	2.3	105
92	Effect of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue at Breast MR Imaging. Radiology, 2012, 264, 670-678.	3.6	74
93	Background Parenchymal Enhancement at Breast MR Imaging and Breast Cancer Risk. Radiology, 2011, 260, 50-60.	3.6	292
94	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
95	Markers of inflammation and risk of ovarian cancer in Los Angeles County. International Journal of Cancer, 2009, 124, 1409-1415.	2.3	100
96	Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer, 2009, 115, 531-539.	2.0	97
97	Relationships between body mass index, endogenous estrogen levels, and patterns of estrogen metabolism in Asian–American women. FASEB Journal, 2009, 23, 551.33.	0.2	0
98	Impact of Ethnicity On Incidence and Survival Among Adults with Acute Lymphoblastic Leukemia in the United States; Insights From 2005 SEER Data.. Blood, 2009, 114, 3069-3069.	0.6	0
99	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	2.3	73
100	Multiple regions within 8q24 independently affect risk for prostate cancer. Nature Genetics, 2007, 39, 638-644.	9.4	621
101	Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genetics, 2005, preprint, e68.	1.5	6
102	Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertility and Sterility, 2004, 82, 186-195.	0.5	122
103	Green tea and risk of breast cancer in Asian Americans. International Journal of Cancer, 2003, 106, 574-579.	2.3	226
104	Postmenopausal Hormone Therapy and Change in Mammographic Density. Journal of the National Cancer Institute, 2003, 95, 30-37.	3.0	388
105	Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 795-800.	1.1	85
106	Genetic variation of 3β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk. , 1997, 33, 9-12.		63
107	The Endocrine Prevention of Breast Cancer. Cancer Investigation, 1995, 13, 495-504.	0.6	26
108	A case-control interview study of breast cancer among Japanese A-bomb survivors. I. Main effects. Cancer Causes and Control, 1994, 5, 157-165.	0.8	37

#	Article	IF	Citations
109	A case-control interview study of breast cancer among Japanese A-bomb survivors. II. Interactions with radiation dose. Cancer Causes and Control, 1994, 5, 167-176.	0.8	74
110	The chemoprevention of breast cancer by reducing sex steroid exposure: Perspectives from epidemiology. Journal of Cellular Biochemistry, 1993, 53, 26-36.	1.2	18
111	The Prevention of Breast Cancer through Reduced Ovarian Steroid Exposure. Acta OncolÃ³gica, 1992, 31, 167-174.	0.8	31
112	<i>Response</i> : Cancer and the Environment. Science, 1992, 255, 904-904.	6.0	0
113	Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer, 1991, 68, 2466-2472.	2.0	232
114	Cigarette smoking in pregnancy results in marked decrease in maternal hCG and oestradiol levels. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 92-96.	1.1	84
115	Statistical errors invalidate conclusions in â€œcaffeine and unsaturated fat diet significantly promotes DMBA-induced breast cancer in ratsâ€. Cancer, 1985, 55, 1855-1857.	2.0	2
116	Remark on â€œAlgorithm 179: Incomplete Beta Ratio [S14]â€. ACM Transactions on Mathematical Software, 1976, 2, 207-208.	1.6	1
117	Clustering of Cancer. Ca-A Cancer Journal for Clinicians, 1975, 25, 230-234.	157.7	3
118	Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intra-Uterine Contraceptive System. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	0